AC Immune SA - ESG Rating & Company Profile powered by AI
The assessment of AC Immune SA leverages information from across the web and also from available documents by AC Immune SA. This SDG score for AC Immune SA indicates the company's reporting of the UN Sustainable Development Goals. This ESG rating includes 17 UN SDGs including: 'Good Health & Wellbeing', 'Responsible Production & Consumption' and 'Partnerships for the Goals'.
AC Immune SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.5; made up of an environmental score of 2.0, social score of 8.0 and governance score of 6.4.
5.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 602 | SkinBioTherapeutics PLC | 5.6 | High |
| 602 | XOMA Corp | 5.6 | High |
| 627 | AC Immune SA | 5.5 | High |
| 627 | Advanced Medical Solutions Group PLC | 5.5 | High |
| 627 | Achieve Life Sciences Inc | 5.5 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does AC Immune SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes AC Immune SA disclose current and historical energy intensity?
Sign up for free to unlockDoes AC Immune SA report the average age of the workforce?
Sign up for free to unlockDoes AC Immune SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes AC Immune SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes AC Immune SA disclose cybersecurity risks?
Sign up for free to unlockDoes AC Immune SA offer flexible work?
Sign up for free to unlockDoes AC Immune SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes AC Immune SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes AC Immune SA conduct supply chain audits?
Sign up for free to unlockDoes AC Immune SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes AC Immune SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes AC Immune SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes AC Immune SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes AC Immune SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes AC Immune SA disclose water use targets?
Sign up for free to unlockDoes AC Immune SA have careers partnerships with academic institutions?
Sign up for free to unlockDid AC Immune SA have a product recall in the last two years?
Sign up for free to unlockDoes AC Immune SA disclose incidents of discrimination?
Sign up for free to unlockDoes AC Immune SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas AC Immune SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes AC Immune SA disclose parental leave metrics?
Sign up for free to unlockDoes AC Immune SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes AC Immune SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes AC Immune SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes AC Immune SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes AC Immune SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes AC Immune SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs AC Immune SA involved in embryonic stem cell research?
Sign up for free to unlockDoes AC Immune SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes AC Immune SA disclose its waste policy?
Sign up for free to unlockDoes AC Immune SA report according to TCFD requirements?
Sign up for free to unlockDoes AC Immune SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes AC Immune SA disclose energy use targets?
Sign up for free to unlockDoes AC Immune SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes AC Immune SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for AC Immune SA
These potential risks are based on the size, segment and geographies of the company.
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.